Cargando…

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors

AIM: To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. MATERIALS & METHODS: This is a retrospective review of 50 non-small-cell lung cancer patients receiving ICIs with metformin (cohort A) or without metformin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afzal, Muhammad Z, Dragnev, Konstantin, Sarwar, Tayyaba, Shirai, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802712/ https://www.ncbi.nlm.nih.gov/pubmed/31645894 http://dx.doi.org/10.2217/lmt-2018-0016

Ejemplares similares

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2023)

Does denosumab offer survival benefits? —Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors
por: Cao, Yenong, et al.
Publicado: (2021)

Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Series
por: Palmer, John P., et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
por: Rojas, Frank, et al.
Publicado: (2022)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Yang, Jieun, et al.
Publicado: (2022)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Immune checkpoint inhibitor‐related haemophagocytic lymphohistiocytosis in a patient with non‐small cell lung carcinoma
por: Oyama, Setsuko, et al.
Publicado: (2023)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
por: Lai, Anne Y, et al.
Publicado: (2020)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020)

Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations
por: Dragnev, Konstantin H., et al.
Publicado: (2023)

Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer
por: Phua, Chun Seng, et al.
Publicado: (2020)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
por: Schlick, Brian, et al.
Publicado: (2022)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response
por: Hassan, Mubariz A, et al.
Publicado: (2023)

Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
por: Chen, Xiuqiong, et al.
Publicado: (2022)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qskmr690mp4ch9mhkg70fpea4d